secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001787306-23-000122
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis reports Q3 2023 total revenue of $38.1M, ZORYVE sales up 70% QoQ to $8.1M
--------------------------------------------------------------------------------

- Net loss $44.8M ($0.73 EPS) vs loss $107.7M ($1.89 EPS) in Q3 2022; R&D expense down to $26.2M.
- ZORYVE plaque psoriasis prescriptions over 110k from nearly 9k prescribers; FDA approved expanded indication to children ages 6+.
- sNDA submitted for roflumilast cream 0.15% for atopic dermatitis ages 6+; potential approval Q3 2024.
- Completed $100M public offering in Oct 2023; amended SLR debt facility removing market cap covenant, requires $31M additional capital by Apr 2024.
- Appointed Todd Edwards CCO and John Smither interim CFO; Huadong collaboration upfront $30M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000122/0001787306-23-000122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000122/arqt-20231103.htm
  HTML page:      https://secwatch.observer/filing/0001787306-23-000122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer